Why the FDA Approval Process Exists

The U.S. Food and Drug Administration (FDA) is responsible for ensuring that drugs sold in the United States are safe and effective for their intended uses. The approval process is a systematic, evidence-based review designed to protect public health — balancing the need for rigorous safety standards against the urgency patients may feel for new treatments.

The journey from a promising compound to an approved medication typically takes many years, though expedited pathways exist for serious conditions with unmet medical need.

Step 1: Preclinical Research

Before any human testing can begin, a drug candidate must undergo extensive preclinical studies — in vitro (cell-based) and in vivo (animal) experiments. These studies assess basic safety, pharmacological activity, and toxicology. Only compounds that show acceptable safety profiles and sufficient pharmacological promise advance to human trials.

Step 2: Investigational New Drug (IND) Application

To begin human clinical trials in the U.S., a sponsor (typically a pharmaceutical company or research institution) must submit an Investigational New Drug (IND) application to the FDA. This application includes preclinical data, proposed clinical trial protocols, manufacturing information, and investigator qualifications.

The FDA has 30 days to review the IND and raise any concerns. If no clinical hold is issued, trials can proceed.

Step 3: Clinical Trials (Phases I–III)

The drug then progresses through the three phases of clinical trials — Phase I (safety), Phase II (efficacy signals), and Phase III (large-scale confirmation). This is typically the longest and most costly phase of drug development, spanning several years and potentially thousands of patients across multiple study sites.

Step 4: New Drug Application (NDA)

If clinical trial results are positive, the sponsor submits a New Drug Application (NDA) to the FDA. The NDA is a comprehensive dossier containing all clinical, preclinical, and manufacturing data gathered during development. FDA reviewers — including physicians, pharmacologists, statisticians, and chemists — evaluate the entire body of evidence.

Step 5: FDA Review

The FDA has a standard review period of 10 months for most applications, or 6 months for priority review designations (granted for drugs that offer a significant improvement over available therapies). During this period, the FDA may also convene an advisory committee — a panel of independent experts who provide recommendations, though the FDA is not bound by their advice.

Step 6: Approval (or Complete Response Letter)

The FDA may approve the drug, potentially with required labeling modifications or post-marketing study commitments. Alternatively, it may issue a Complete Response Letter (CRL), outlining deficiencies the sponsor must address before approval can be granted.

Expedited Approval Pathways

The FDA offers several programs to accelerate development and review of promising therapies for serious conditions:

  • Fast Track: Facilitates more frequent communication with FDA during development
  • Breakthrough Therapy: Intensive guidance for drugs showing substantial improvement over existing therapies
  • Accelerated Approval: Allows approval based on surrogate endpoints with post-marketing confirmation required
  • Priority Review: Shortens review timeline to 6 months

After Approval: Ongoing Oversight

FDA oversight doesn't end at approval. Post-marketing surveillance, Phase IV studies, and MedWatch (the FDA's adverse event reporting system) ensure that safety signals emerging in the real world are captured and acted upon — including label updates or, in rare cases, market withdrawal.

Understanding this process underscores why FDA-approved drugs represent a meaningful standard of evidence-based medicine.